Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine

Claudio Luchini, Nicola Veronese, Alessia Nottegar, Vera Cappelletti, Maria G. Daidone, Lee Smith, Christopher Parris, Lodewijk A.A. Brosens, Maria G. Caruso, Liang Cheng, Christopher L. Wolfgang, Laura D. Wood, Michele Milella, Roberto Salvia, Aldo Scarpa

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.

Original languageEnglish (US)
Article number1152
JournalCancers
Volume11
Issue number8
DOIs
StatePublished - Aug 2019

Fingerprint

Precision Medicine
Pancreatic Neoplasms
Meta-Analysis
Biopsy
Mutation Rate
Sensitivity and Specificity
ROC Curve
Area Under Curve
Odds Ratio
Genes
Neoplasms
Therapeutics

Keywords

  • CfDNA
  • Circulating tumor cells (CTC)
  • Liquid biopsy
  • Pancreatic cancer
  • Precision medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Luchini, C., Veronese, N., Nottegar, A., Cappelletti, V., Daidone, M. G., Smith, L., ... Scarpa, A. (2019). Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine. Cancers, 11(8), [1152]. https://doi.org/10.3390/cancers11081152

Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer : A meta-analysis towards precision medicine. / Luchini, Claudio; Veronese, Nicola; Nottegar, Alessia; Cappelletti, Vera; Daidone, Maria G.; Smith, Lee; Parris, Christopher; Brosens, Lodewijk A.A.; Caruso, Maria G.; Cheng, Liang; Wolfgang, Christopher L.; Wood, Laura D.; Milella, Michele; Salvia, Roberto; Scarpa, Aldo.

In: Cancers, Vol. 11, No. 8, 1152, 08.2019.

Research output: Contribution to journalReview article

Luchini, C, Veronese, N, Nottegar, A, Cappelletti, V, Daidone, MG, Smith, L, Parris, C, Brosens, LAA, Caruso, MG, Cheng, L, Wolfgang, CL, Wood, LD, Milella, M, Salvia, R & Scarpa, A 2019, 'Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine', Cancers, vol. 11, no. 8, 1152. https://doi.org/10.3390/cancers11081152
Luchini, Claudio ; Veronese, Nicola ; Nottegar, Alessia ; Cappelletti, Vera ; Daidone, Maria G. ; Smith, Lee ; Parris, Christopher ; Brosens, Lodewijk A.A. ; Caruso, Maria G. ; Cheng, Liang ; Wolfgang, Christopher L. ; Wood, Laura D. ; Milella, Michele ; Salvia, Roberto ; Scarpa, Aldo. / Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer : A meta-analysis towards precision medicine. In: Cancers. 2019 ; Vol. 11, No. 8.
@article{8690b0a24afc49f091b4ab8f45b5d2f2,
title = "Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine",
abstract = "Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9{\%}. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.",
keywords = "CfDNA, Circulating tumor cells (CTC), Liquid biopsy, Pancreatic cancer, Precision medicine",
author = "Claudio Luchini and Nicola Veronese and Alessia Nottegar and Vera Cappelletti and Daidone, {Maria G.} and Lee Smith and Christopher Parris and Brosens, {Lodewijk A.A.} and Caruso, {Maria G.} and Liang Cheng and Wolfgang, {Christopher L.} and Wood, {Laura D.} and Michele Milella and Roberto Salvia and Aldo Scarpa",
year = "2019",
month = "8",
doi = "10.3390/cancers11081152",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer

T2 - A meta-analysis towards precision medicine

AU - Luchini, Claudio

AU - Veronese, Nicola

AU - Nottegar, Alessia

AU - Cappelletti, Vera

AU - Daidone, Maria G.

AU - Smith, Lee

AU - Parris, Christopher

AU - Brosens, Lodewijk A.A.

AU - Caruso, Maria G.

AU - Cheng, Liang

AU - Wolfgang, Christopher L.

AU - Wood, Laura D.

AU - Milella, Michele

AU - Salvia, Roberto

AU - Scarpa, Aldo

PY - 2019/8

Y1 - 2019/8

N2 - Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.

AB - Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.

KW - CfDNA

KW - Circulating tumor cells (CTC)

KW - Liquid biopsy

KW - Pancreatic cancer

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85073276091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073276091&partnerID=8YFLogxK

U2 - 10.3390/cancers11081152

DO - 10.3390/cancers11081152

M3 - Review article

AN - SCOPUS:85073276091

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1152

ER -